Note: Applies to ovarian primary tumor. If bilateral tumors of 2 different histologic types are present, separate checklists should be used for each tumor.

Specimen:
   Right ovary
   Left ovary
   Right fallopian tube
   Left fallopian tube
   Uterus
   Cervix
   Omentum
   Peritoneum
   Other (specify):
   Not specified
   Cannot be determined

Procedure:
   Right oophorectomy
   Left oophorectomy
   Right salpingo-oophorectomy
   Left salpingo-oophorectomy
   Bilateral salpingo-oophorectomy
   Subtotal right oophorectomy
   Subtotal left oophorectomy
   Supracervical hysterectomy
   Hysterectomy
   Omentectomy
   Peritoneal biopsies
   Other (specify):
   Not specified

Lymph Node Sampling:
Performed
Not performed
Not known

Specimen Integrity:
       Right Ovary:
        Not applicable
        Capsule intact
        Capsule ruptured
        Fragmented
        Other (specify):
       Left Ovary:
        Not applicable
        Capsule intact
        Capsule ruptured
        Fragmented
        Other (specify):

Primary Tumor Site:
   Right ovary
   Left ovary
   Bilateral ovarian involvement
   Not specified

Ovarian Surface Involvement:
Present
Absent
Uncertain/cannot be determined

Tumor Size:
   Right Ovary: cm
   Left Ovary: cm

Histologic Type:
   Serous, borderline tumor
   Serous, carcinoma
   Mucinous, borderline tumor, intestinal type
   Mucinous, borderline tumor, endocervical type (seromucinous type)
   Mucinous carcinoma
   Endometrioid borderline tumor
   Endometrioid carcinoma
   Clear cell borderline tumor
   Clear cell carcinoma
   Transitional cell borderline tumor
   Transitional cell carcinoma
   Brenner tumor, malignant type
   Squamous cell carcinoma
   Mixed epithelial borderline tumor (specify types and percentages):
   Mixed epithelial carcinoma (specify types and percentages):
   Undifferentiated carcinoma
   Carcinosarcoma (Malignant müllerian mixed tumor)
   Granulosa cell tumor
   Other sex cord-stromal tumor (specify type):
   Malignant germ cell tumor (specify types and percentages):
   Other(s) (specify):

Histologic Grade:
World Health Organization (WHO) Grading System(applies to all carcinomas, including serous carcinomas):
    GX: Cannot be assessed
    G1: Well differentiated
    G2: Moderately differentiated
    G3: Poorly differentiated
    G4: Undifferentiated
Two-Tier Grading System (may be applied to serous carcinomas and immature teratomas only):
    Low grade
    High grade
Other (specify):
Not applicable

Implants (only applies to advanced stage serous/seromucinous borderline tumors):
       Not applicable/not sampled
       Noninvasive Implant(s):
           Not present
           Present (specify sites):
           Epithelial
           Desmoplastic
       Invasive Implant(s):
           Not present
           Present (specify sites):

Extent of Involvement of Other Tissues/Organs:
   Right ovary:
    Involved
    Not involved
    Not applicable
   Left ovary:
    Involved
    Not involved
    Not applicable
   Right fallopian tube:
    Involved
    Not involved
    Not applicable
   Left fallopian tube:
    Involved
    Not involved
    Not applicable
   Omentum:
    Involved
    Not involved
    Not applicable
   Uterus:
    Involved (specify location: )
    Not involved
    Not applicable
   Peritoneum:
    Involved
    Not involved
    Not applicable
   Other organs/tissues (specify):

Treatment Effect (applicable to carcinomas treated with neoadjuvant therapy):
    No definite or minimal response identified (poor or no response)
    Marked response (minimal residual cancer)

Lymph-Vascular Invasion:
    Not identified
    Present
    Indeterminate

Pathologic Staging (pTNM FIGO):
m (multiple primary tumors)
r (recurrent)
y (posttreatment)

Primary Tumor (pT):
pTX (--): Cannot be assessed
pT0 (--): No evidence of primary tumor
pT1 (I): Tumor limited to ovaries (one or both)
pT1a (IA): Tumor limited to one ovary; capsule intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings Nonmalignant ascites is not classified. The presence of ascites does not affect staging unless malignant cells are present.
pT1b (IB): Tumor limited to both ovaries; capsule intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings
pT1c (IC): Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings
pT2 (II): Tumor involves one or both ovaries with pelvic extension and/or implants
pT2a (IIA): Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings
pT2b (IIB): Extension to other pelvic tissues. No malignant cells in ascites or peritoneal washings
pT2c (IIC): Pelvic extension and/or implants (T2a or T2b / IIa or IIb) with malignant cells in ascites or peritoneal washings
pT3 and/or N1 (III): Tumor involves one or both ovaries with confirmed peritoneal metastasis outside the pelvis (including liver capsule metastasis and/or regional lymph node metastasis N1)
pT3a (IIIA): Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor)
pT3b (IIIB): Macroscopic peritoneal metastasis beyond pelvis <=2 cm in greatest dimension
pT3c and/or N1 (IIIC): Peritoneal metastasis beyond pelvis >2 cm in greatest dimension and/or regional lymph node metastasis

Regional Lymph Nodes (pN):
pNX: Cannot be assessed
pN0: No regional lymph node metastasis (0 / )
pN1 (IIIC): Regional lymph node metastasis ( / )
No nodes submitted or found

Distant Metastasis (pM):
    Not applicable
    pM1 (IV): Distant metastases (excludes peritoneal metastasis) specify sites:

Note: If pleural effusion is present, there must be a positive cytology for a stage IV designation. Parenchymal liver metastasis is classified as stage IV disease, whereas liver capsule metastasis is classified as stage III disease.

Additional Pathologic Findings:
       None identified
       Endometriosis:
           Ovarian
           Extraovarian
       Endosalpingiosis
       Other(s):

Ancillary Studies:

Clinical History:
       BRCA1/2 family history
       Hereditary breast/ovarian cancer
       Other (specify):

Comment(s):